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To the editor.  
We read the recently published letter to the editor by 
Dr. Girolami and Dr. Ferrari.1 While it does not add 
anything novel to our knowledge on severe prekallikrein 
(PK) deficiency, it misleadingly reported on recent 
works, which showed for the first time the much higher 
than the anticipated prevalence of severe PK deficiency 
among subjects of African origin.2,3 Finally, Girolami 
and Ferrari cited multiple reviews of the literature 
characterized by inadequate methodology for systematic 
searches without, in contrast, citing the sole 
comprehensive analysis of the clinical, laboratory, and 
genetic characteristics of severe PK deficiency.2 
Furthermore, they discredited a follow-up paper as 
preliminary.3 
In May 2020, we published a systematic study on 
severe PK deficiency,2 the results of which had 
previously been presented at the American Society of 
Hematology Congress in December 2018.4 Among other 
findings, including the demonstration that some KLKB1 
variants previously described in the literature as causal 
mutations for PK deficiency represented, in fact, benign 
polymorphisms, we reported two African patients from 
Ghana and Somalia, respectively, with the same 
homozygous KLKB1 variant (c.451dupT, 
p.Ser151Phefs*34). This variant has not been noticed in 
the international literature so far, despite a minor allele 
frequency of 1.43% for African subjects, according to 
the large Genome Aggregation Database (gnomAD). 
This datum suggests that severe PK deficiency in 
Africans could be as common as 1/4725 general 
population just based on this unique mutation, which 
appears predominant in this ethnic group,2 but is much 
less common in other groups. In a follow-up project 
intended to substantiate the high prevalence of the 
KLKB1 c.451dupT mutation in African origin subjects,3 
we investigated 300 healthy Nigerians and confirmed a 
high allele frequency (7/600 alleles corresponding to 
1.17%). In this manuscript, we provided a more detailed 
analysis of the variant's frequency also by looking at 
other genome databases, again confirming the high 
frequency in African populations of different origin 
(native African, African-American, and Afro-
Caribbean).3 In addition, in another severe PK deficient 
patient from Oman identified in,2 we found out that he 
was also a homozygous carrier of c.451dupT,3 and we 
identified another homozygous c.451dupT carrier from 
the literature,5 which turned out to be American of 
African origin after personal communication with one of 
the authors (the ethnicity was not mentioned in the 
manuscript).  
Based on the aforementioned elements, we conclude 
that Girolami and Ferrari's letter to the editor is, at least, 
misleading.1 In particular, the sentence "defect present 
in 1.27% of 300 Nigerians" is at the same time imprecise 
(it is unclear whether they refer to the minor allele 
frequency or the prevalence of severe PK deficiency) 
and incorrect (in our manuscript, a value of 1.17% was 
reported). Moreover, and as detailed above, this 
published data is far more than "preliminary", having 
been confirmed using data from different cohorts and 
databases.2,3 It comes indeed as a surprise that this 
evidence has then been embraced by Drs. Girolami and 
Ferrari without citing the original works correctly2 or, as 
it is the case in a brief more recent communication from 
the same authors on the same topic, not citing them at 
all.6 
Finally, and beyond the discussion on the actual 
prevalence of severe PK deficiency, we believe that our 
estimates of bleeding and cardiovascular risks2 represent 
the most reliable figures available in the literature. 
Reasons for that are that (i) these are provided both as 
age-stratified and depending on individual follow-up 
time, (ii) prior analyses erroneously presented 
duplicated data from different reports of the same case, 
(iii) the process of the systematic review was conducted 
with adequate and transparent methodology, also 
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covering the grey literature and describing each step of 
study selection in great detail.2 
Multinational cooperation involving global 
coagulation experts is being set up to conduct the first 
international registry on severe PK deficiency and 
answer open questions on this condition.
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